Fintel reports that on May 20, 2026, Freedom Broker upgraded their outlook for aTyr Pharma (NasdaqCM:ATYR) from Hold to Buy.
Analyst Price Forecast Suggests 1,242.49% Upside
As of May 14, 2026, the average one-year price target for aTyr Pharma is $6.48/share. The forecasts range from a low of $1.01 to a high of $21.00. The average price target represents an increase of 1,242.49% from its latest reported closing price of $0.48 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for aTyr Pharma is 83MM, an increase of 43,778.42%. The projected annual non-GAAP EPS is -0.04.
What is the Fund Sentiment?
There are 114 funds or institutions reporting positions in aTyr Pharma. This is an decrease of 55 owner(s) or 32.54% in the last quarter. Average portfolio weight of all funds dedicated to ATYR is 0.00%, an increase of 94.43%. Total shares owned by institutions increased in the last three months by 4.58% to 61,323K shares. 
The put/call ratio of ATYR is 0.09, indicating a bullish outlook.
What are Other Shareholders Doing?
Federated Hermes holds 10,510K shares representing 10.72% ownership of the company. No change in the last quarter.
UBS Group holds 3,867K shares representing 3.94% ownership of the company. In its prior filing, the firm reported owning 1,625K shares , representing an increase of 57.97%. The firm increased its portfolio allocation in ATYR by 119.37% over the last quarter.
Vanguard Capital Management holds 3,812K shares representing 3.89% ownership of the company.
Geode Capital Management holds 2,385K shares representing 2.43% ownership of the company. In its prior filing, the firm reported owning 2,284K shares , representing an increase of 4.27%. The firm decreased its portfolio allocation in ATYR by 43.96% over the last quarter.
Gsa Capital Partners Llp holds 1,685K shares representing 1.72% ownership of the company. In its prior filing, the firm reported owning 2,631K shares , representing a decrease of 56.16%. The firm decreased its portfolio allocation in ATYR by 53.96% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
